PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) “Gets It Right” in Cannabinoid Extraction
Sol-gel nose-to-brain system offers superior drug delivery New extraction protocol makes accurate and precise quantification of cannabinoids possible Establishment of cannabis division to commercialize research developments A recent release from PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) shows that, in cannabinoid extraction technology, the health sciences company is getting it right. The company announced that, during its soluble gel drug delivery research and development program – the Sol-gel Program – it had successfully optimized the conditions for extracting cannabinoids from one of its cannabis strains and developed a proprietary method – the Extraction Protocol – for the accurate…